RxSight: Unique Adjustable IOL Technology Offset by Slowing Momentum and Execution Risks Supports Hold Rating

RxSight (RXST) has received a new Hold rating, initiated by William Blair analyst, .

William Blair has given his Hold rating due to a combination of factors reflecting both RxSight’s differentiated technology and its recent operational challenges. The firm recognizes that RxSight offers a unique adjustable intraocular lens in a large and growing premium cataract market, and that the stock currently trades at a notable valuation discount versus peers. However, sales momentum has weakened, with 2025 revenue declining year over year and newer surgeon cohorts not scaling their procedure volumes as rapidly as earlier adopters. Competitive pressure from larger rivals and the added logistical burden of extra post-operative visits for the adjustable lens are weighing on utilization.

William Blair’s stance also reflects concerns about execution and the balance of near-term risks and rewards. Management is reallocating resources away from aggressive new customer acquisition toward improving support and education for existing accounts, which may be necessary but could limit growth acceleration in the short term. The company does not have major product launches on the immediate horizon, making a swift inflection in demand less certain despite continued incremental improvements to the lens platform. While potential strategic interest in RxSight is acknowledged, the analysts want to see clear, sustained benefits from the new customer engagement initiatives before moving to a more constructive rating, leading them to conclude that a Hold (Market Perform) rating is most appropriate at this time.

In another report released today, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $9.00 price target.